2-acetoxymethyl-5-methyl pyridine | 772-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-acetoxymethyl-5-methyl pyridine
• 英文别名: acetic acid 5-methylpyridin-2-ylmethyl ester；2-acetoxymethyl-5-methyl-pyridine；acetic acid-(5-methyl-[2]pyridylmethyl ester)；Essigsaeure-(5-methyl-[2]pyridylmethylester)；acetic acid 5-methyl-pyridin-2-ylmethyl ester；2-acetoxymethyl-5-methylpyridine；(5-methylpyridin-2-yl)methyl acetate
• CAS: 772-71-4
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: GGOIBOIDGMTXLN-UHFFFAOYSA-N

物化性质

• 沸点：
  124-124 °C(Press: 15 Torr)
• 密度：
  1.088±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-acetoxymethyl-5-methyl pyridine 在 盐酸 、 sodium hydroxide 、 乙醇 、 乙酸乙酯 、 三氯氧磷 作用下， 生成 2,5-二甲基吡啶
  参考文献：
  名称：

  Arata; Achiwa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1959, vol. 79, p. 108

  摘要：

  DOI：
• 作为产物：
  描述：

  2,5-二甲基吡啶 在 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 49.5h， 生成 2-acetoxymethyl-5-methyl pyridine
  参考文献：
  名称：

  5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor

  摘要：

  The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc is described (AM803, now GSK2190915). Building upon AM103 (1) (Hutchinson et al. J. Med Chem. 2009, 52, 5803-5815; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 213-217; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 4598-4601), SAR studies centering around the pyridine moiety led to the discovery of compounds that exhibit significantly increased potency in a human whole blood assay measuring LTB4 inhibition with longer drug preincubation times (15 min vs S h). Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood (5 h incubation) and excellent preclinical toxicology and pharmacoldnetics in rat and dog. 11cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. This compound has successfully completed phase 1 clinical studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.

  DOI：

  10.1021/jm2008369

文献信息

• Die Reaktion von 3-Butyl-pyridin mit Methylradikalen
  作者：E. Hardegger、E. Nikles

  DOI：10.1002/hlca.19570400738

  日期：——

  3-Butyl-pyridin gab mit Methylradikalen ein kompliziertes Gemisch mono-, di- und höher rnethylierter Verbindungen, welches qualitativ und quantitativ genauer untersucht wurde. Unter den mono methylierten Produkten herrscht das 3-Butyl-2-methyl-pyridin vor; 3-Butyl-4-methyl- und 5-Butyl-2-methyl-pyridin sind etwa zu gleichen Teilen vorhanden; 3-Butyl-5-methyl-pyridin entsteht kaum. Die Konstitution des

  3-丁基吡啶g甲基丙烯酸单丁酯，二乙基己酸酯和二甲苯，可用于定性和定量分析。Unter den monomethylierierten Produkten herrscht das 3-Butyl-2-methyl-pyridin vor; 3-丁基-4-甲基-和5-丁基-2-甲基-吡啶 3-丁基-5-甲基-吡啶表示kaum。Die Konstitution des 3-Butyl-4-methyl-pyridins wurde durch Abbau zumγ-Picolin bewiesen。芦苇形式的3-丁-二甲基-吡啶异丁烯的芳烃衍生物。和二苯并呋喃酮和3-丁基-2,6-二甲基-吡啶二烷。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson H. John

  公开号：US20070105866A1

  公开（公告）日：2007-05-10

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本发明描述了调节5-脂氧合酶激活蛋白(FLAP)活性的化合物和含有该化合物的药物组合物。本发明还描述了单独使用和与其他化合物联合使用FLAP调节剂，用于治疗呼吸系统、心血管系统和其他白三烯依赖性或白三烯介导的状况或疾病。
• [EN] REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR<br/>[FR] RÉDUCTION DE HDL PRO-INFLAMMATOIRE À L'AIDE D'UN INHIBITEUR DE LEUCOTRIÈNE
  申请人：AUTOIMMUNE PHARMA LLC

  公开号：WO2018152405A1

  公开（公告）日：2018-08-23

  A method involving the administration of a therapeutically effective amount of a leukotriene inhibitor, a pharmaceutically acceptable salt, a pharmaceutically acceptable N-oxide, a pharmaceutically active metabolite, a pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof to a human for reducing a level of pro-inflammatory HDL in the human. Various examples of leukotriene inhibitors, including 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin- 3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2, 2-dimethyl-propionic acid, are disclosed for administration for the reduction of pro-inflammatory HDL in a human. Reduction of pro-inflammatory HDL by the leukotriene inhibitor may include conversion of at least a portion of pro-inflammatory HDL to anti-inflammatory HDL.

  一种方法，涉及给人类施用治疗有效量的白细胞三烯抑制剂、药物可接受的盐、药物可接受的N-氧化物、药物活性代谢物、药物可接受的的前药或其药物可接受的溶剂化物，以降低人类中的前炎症高密度脂蛋白(HDL)水平。公开了各种白细胞三烯抑制剂，包括3-[3-叔丁基硫基-1-[4-(6-乙氧基-吡啶-3-基)-苄基]-5-(5-甲基-吡啶-2-基甲氧基)-1H-吲哚-2-基]-2,2-二甲基丙酸，用于施用以降低人类中的前炎症HDL。通过白细胞三烯抑制剂降低前炎症HDL可能包括将至少部分前炎症HDL转化为抗炎症HDL。
• 2-[(2-Pyridylmethyl)sulfinyl]-1H-thieno[3,4-d]imidazoles. A novel class of gastric H+/K+-ATPase inhibitors
  作者：Klaus Weidmann、Andreas W. Herling、Hans Jochen Lang、Karl Heinz Scheunemann、Robert Rippel、Hildegard Nimmesgern、Thomas Scholl、Martin Bickel、Heinz Metzger

  DOI：10.1021/jm00081a004

  日期：1992.2

  2-[(2-Pyridylmethyl)sulfinyl]thienoimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K(+)-ATPase. The [3,4-d] isomers of the two possible thienoimidazole series were found to be potent inhibitors of gastric acid secretion in vitro and in vivo. Structure-activity relationships indicate that especially lipophilic alkoxy, benzyloxy, and phenoxy substituents with additional

  合成2-[（（2-吡啶基甲基）亚磺酰基]噻吩并咪唑类化合物，并研究其作为胃H + / K（+）-ATPase的潜在抑制剂。已发现两种可能的噻吩并咪唑系列的[3,4-d]异构体在体外和体内都是有效的胃酸分泌抑制剂。结构活性关系表明，特别是在吡啶部分的4位具有额外的电子要求特性的亲脂性烷氧基，苄氧基和苯氧基取代基与未取代的噻吩并[3,4-d]咪唑结合会导致具有高活性的化合物。良好的化学稳定性。噻吩并[3,4-d]咪唑部分的各种取代方式导致较低的生物活性。选择了七氟丁氧基衍生物萨维拉唑（HOE 731，5d）进行进一步开发，目前正在临床评估中。
• Naphth[2,3-d]imidazoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US04182766A1

  公开（公告）日：1980-01-08

  Imidazole derivatives of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 R.sub.4, R.sub.5, X and n are as hereinafter set forth, and pharmaceutically acceptable acid addition salts thereof, are described. The compounds of formula I are useful in the treatment of gastric ulcers.

  公式为##STR1##的咪唑衍生物，其中R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、X和n如下所述，以及其药用酸盐，已被描述。公式I的化合物在治疗胃溃疡方面是有用的。